stockrow
Saturday 7 November 2026
Export CTNM’s income statement to Excel — free account
Contineum Therapeutics, Inc.
CTNM Healthcare Biotechnology
Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million.
- EPS
- −8.22%
- Free cash flow
- +10.0%
Quarter to September 2026, against a year earlier
9.42
0.61
+6.92%
Follow CTNM
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
— | — | 1.35 | — |
P/S ratio |
— | — | 0.00 | — |
P/FCF ratio |
— | — | 2.26 | — |
Altman Z″-Score (non-manufacturers) |
— | — | 4.74 | — |
P/Operating CF |
— | — | (4.57) | — |
P/B ratio |
— | — | 0.00 | — |
Price to Tangible BV |
— | — | 0.00 | — |
EV/Sales |
— | — | 0.00 | — |
EV/EBITDA |
— | — | 0.00 | — |
EV/Operating CF |
— | — | (4.87) | — |
EV/FCF |
— | — | (5.03) | — |
Quick Ratio |
26.98 | 20.53 | 22.83 | 6.26 |
Current Ratio |
27.50 | 20.69 | 23.29 | 6.41 |
Net Debt/EBITDA |
3.88 | 4.02 | (7.76) | 1.95 |
Debt/Assets |
0.00% | 0.68% | 0.36% | 7.80% |
Debt/Equity |
0.00 | 0.01 | (0.01) | (0.04) |
Asset Turnover |
0.00 | 0.00 | 0.55 | — |
Operating CF/Net income |
0.92 | 0.78 | 6.15 | 0.83 |
Capex/Depreciation |
(0.72) | (1.91) | 138.00 | (0.24) |
Interest Coverage |
— | — | 77.29 | (58.56) |
| (26.13%) | (64.95%) | (3.90%) | 0.00% | |
| (24.51%) | (24.62%) | 3.48% | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(23.16%) | (21.41%) | 2.56% | (58.76%) |
Average Days of Receivables |
— | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 55.21% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 12.64% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 4.44% | 0.00% |
Graham Net Nets |
— | — | (2.18) | — |
Graham Number |
— | — | 0.00 | — |
Earnings Yield |
— | — | 73.93% | — |
Free Cash Flow Yield |
— | — | 44.16% | — |
Revenue per Share |
0.00 | 0.00 | 21.65 | 0.00 |
Operating CF per Share |
(2.00) | (1.70) | 8.38 | (8.97) |
Capex per Share |
(0.01) | (0.03) | (0.18) | (0.05) |
Free Cash Flow per Share |
(2.01) | (1.72) | 8.20 | (9.02) |
Cash per Share |
9.49 | 10.58 | 54.22 | 21.06 |
Shareholders Equity per Share |
9.42 | 10.23 | (29.42) | (41.56) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.42 | 10.23 | (29.42) | (41.56) |
Free Cash Flow |
(55.54) | (33.34) | 18.94 | (20.24) |
Working Capital |
258.17 | 196.41 | 122.22 | 40.84 |
Capital Expenditures |
(0.23) | (0.49) | (0.41) | (0.12) |
Net Current Asset Value |
252.26 | 191.61 | (70.62) | (95.46) |
EV/EBIT |
— | — | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 |
Price to Operating Income |
— | — | 3.24 | — |
| Other line items | ||||
Depreciation/Fixed assets |
0.39 | 0.26 | 0.00 | 1.12 |
Cash ROIC |
(10.60%) | (8.25%) | 32.81% | 48.16% |
Accounts Receivable Turnover |
— | — | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
1.41 | 1.22 | 0.53 | — |
Average Assets |
244.74 | 171.62 | 90.51 | — |
Average Common Equity |
229.53 | 65.07 | (80.57) | — |
Columns are period end dates · fundamentals updated 5 Nov 2026